Recent studies suggest that GLP-1 obesity and diabetes medications appear to reduce cancer risk beyond what weight loss alone would explain, prompting researchers to investigate potential anti-inflammatory and metabolic mechanisms.
Cancer Risk Reduction Across Multiple Types
A study that tracked medical records of over 10,000 patients with early-stage cancer found GLP-1s reduced cancer risk in 6 out of 7 cancers examined, with four at statistically significant levels. Breast, liver, colorectal, and non-small cell lung cancer risks declined significantly; kidney and prostate declined somewhat; pancreatic cancer rates were affected the least. For non-small cell lung cancer specifically, the incidence of progression to Stage IV disease was 22.3% for patients not on a GLP-1 versus 10% among people taking GLP-1s.
Another study matched mammogram images to prescription databases and found women between ages 45 and 80 who took GLP-1 drugs were 30% less likely to develop breast cancer. However, researchers note the protective effects appear greater than with other treatments or lifestyle changes. As one radiologist observed, “The weight loss alone just didn’t account for the magnitude of the observed effect.”
Mechanisms Under Investigation
GLP-1 drugs were originally developed as diabetes treatments that alter hormonal makeup in the brain and gut, reducing hunger and slowing digestion. Researchers suspect the drugs may trigger additional metabolic pathways beyond weight loss—potentially reducing inflammation, which is a known driver of cancer, or influencing immune cells. New trials are beginning to examine how GLP-1s might reduce chronic inflammation or immunosuppression. One study plans to follow 40 breast-cancer patients starting tirezepatide, measuring blood samples and tracking cancer markers every six months while biopsying abdominal fat cells to assess hormonal and inflammatory responses.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/glp-1s-appear-to-protect-against-cancer-researchers-are-84298629